RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor
Chakraborty, S.; Jiang, J.; Camallonga, J. V.; Gazgalis, D.; Gero, T. W.; Tavares, M. T.; Dittemore, G.; Tkacik, E.; Jang, D. M.; Ha, B. H.; Gottlieb, F. H.; Levitz, T.; Metivier, R. J.; Schmoker, A. M.; Scott, D. A.; Jeon, H.; Janne, P. A.; Eck, M. J.
Show abstract
Aberrant activation of the RAS/RAF/MEK/ERK pathway is a frequent cause of cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes to prevent activation of MEK by RAF. However, how MEK inhibitor potency varies across the three RAF isoforms remains poorly understood. We profiled seven allosteric MEK inhibitors and observed a striking hierarchy of sensitivity: all most potently inhibited CRAF-driven MEK activation while relatively sparing ARAF-driven activation. We identified point mutations in ARAF and CRAF proximate to the MEK inhibitor binding site that markedly altered inhibitor sensitivity. Using a rational design approach, we developed a more potent inhibitor of ARAF-driven MEK signaling, TWG-07-148. Our cryo-EM structure shows how this acrylamide-containing analog of MEK inhibitor trametinib covalently targets Cys514, a residue unique to ARAF. Our studies highlight the importance of the activating RAF isoform as a determinant of MEK inhibitor sensitivity and provide proof-of-concept for development of MEK inhibitors that more effectively block ARAF-driven MEK signaling via covalent targeting of Cys514.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. 96%
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2 96%
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status 95%
Similar papers in this journal
- DFG-1 residue controls inhibitor binding mode and affinity providing a basis for rational design of kinase inhibitor selectivity 95%
- An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth 94%
- FDA drug repurposing uncovers modulators of dopamine D2 receptor localization via disruption of the NCS-1 interaction 94%
Similar papers in this journal
- Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking 96%
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities 95%
- Structural insights into TRAP association with ribosome-Sec61 complex, and translocon inhibition by a CADA derivative 95%
Similar papers in this journal
- Targeting the Protein-Protein Interaction Between the CDC37 Co-Chaperone and Client Kinases by an Allosteric RAF Dimer Breaker 96%
- Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine 96%
- Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.